Xiongbin Lu was named co-leader of the Experimental and Developmental Therapeutics Research Program at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center.
In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL).
